Goodrx Holdings Inc
NASDAQ:GDRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Goodrx Holdings Inc
NASDAQ:GDRX
|
US |
|
S
|
Signatureglobal (India) Ltd
NSE:SIGNATURE
|
IN |
Goodrx Holdings Inc
GoodRx Holdings Inc., established at the intersection of healthcare and technology, has carved a niche in the American pharmaceutical industry by addressing one of its most notorious challenges: the high cost of prescription medications. Originally founded in 2011, GoodRx aims to ease the financial burden of medication costs for consumers by providing a platform that aggregates drug pricing information from pharmacies across the United States. By doing so, it empowers users to compare prices, identify potential savings, and subsequently make informed decisions about their medication purchases. At its core, GoodRx operates as a digital intermediary; its app and website seamlessly connect consumers with discounted prescription offers through partnerships with pharmacy benefit managers (PBMs) and retail pharmacies.
The company's revenue model is primarily built on a commission and advertising framework. When users select a coupon from GoodRx and purchase at a pharmacy, the company receives a fee from its pharmacy partners or PBMs. Additionally, GoodRx leverages its vast user base, which is largely driven by organic traffic resulting from the essential nature of its service, to generate advertising revenues from pharmaceutical companies and other health-related entities eager to reach consumers actively seeking medication solutions. By continually expanding its services, such as telehealth offerings and a subscription model called GoodRx Gold, the company seeks to deepen its integration into the consumer healthcare experience while maintaining its core mission of providing accessible and affordable medication options.
GoodRx Holdings Inc., established at the intersection of healthcare and technology, has carved a niche in the American pharmaceutical industry by addressing one of its most notorious challenges: the high cost of prescription medications. Originally founded in 2011, GoodRx aims to ease the financial burden of medication costs for consumers by providing a platform that aggregates drug pricing information from pharmacies across the United States. By doing so, it empowers users to compare prices, identify potential savings, and subsequently make informed decisions about their medication purchases. At its core, GoodRx operates as a digital intermediary; its app and website seamlessly connect consumers with discounted prescription offers through partnerships with pharmacy benefit managers (PBMs) and retail pharmacies.
The company's revenue model is primarily built on a commission and advertising framework. When users select a coupon from GoodRx and purchase at a pharmacy, the company receives a fee from its pharmacy partners or PBMs. Additionally, GoodRx leverages its vast user base, which is largely driven by organic traffic resulting from the essential nature of its service, to generate advertising revenues from pharmaceutical companies and other health-related entities eager to reach consumers actively seeking medication solutions. By continually expanding its services, such as telehealth offerings and a subscription model called GoodRx Gold, the company seeks to deepen its integration into the consumer healthcare experience while maintaining its core mission of providing accessible and affordable medication options.
Revenue & EBITDA: Full year 2025 revenue was $796.9 million (up 1% YoY) and adjusted EBITDA was $270.5 million (up 4% YoY), both in line with guidance.
Growth Drivers: Pharma Direct revenue surged 41% YoY in 2025 to $151.4 million, becoming a key growth engine as the business shifts toward manufacturer solutions.
Headwinds: Prescription transactions revenue fell 6% YoY, impacted by the Rite Aid bankruptcy, lower volume in partner programs, and renegotiated economics.
Guidance: 2026 revenue expected between $750–780 million with adjusted EBITDA of at least $230 million, reflecting deliberate investments in Pharma Direct and subscriptions at the expense of near-term margins.
Strategic Shift: Company is prioritizing long-term growth and resilience by focusing on direct-to-consumer and manufacturer partnerships, even as this transition causes near-term revenue and margin pressure.
Subscriptions: Condition-based subscriptions, especially weight loss, show strong early adoption and are expected to contribute more meaningfully in 2026.
Market Position: GoodRx retains its leadership in prescription savings with nearly 300 million annual site visits and deep partnerships across the healthcare ecosystem.
